###begin article-title 0
###xml 51 55 51 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
Polymorphisms, Mutations, and Amplification of the EGFR Gene in Non-Small Cell Lung Cancers
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 4 43 4 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">epidermal growth factor receptor (EGFR)</italic>
###xml 350 389 350 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(CA simple sequence repeat 1 [CA-SSR1])</italic>
###xml 673 677 673 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
The epidermal growth factor receptor (EGFR) gene is the prototype member of the type I receptor tyrosine kinase (TK) family and plays a pivotal role in cell proliferation and differentiation. There are three well described polymorphisms that are associated with increased protein production in experimental systems: a polymorphic dinucleotide repeat (CA simple sequence repeat 1 [CA-SSR1]) in intron one (lower number of repeats) and two single nucleotide polymorphisms (SNPs) in the promoter region, -216 (G/T or T/T) and -191 (C/A or A/A). The objective of this study was to examine distributions of these three polymorphisms and their relationships to each other and to EGFR gene mutations and allelic imbalance (AI) in non-small cell lung cancers.
###end p 2
###begin title 3
Methods and Findings
###end title 3
###begin p 4
###xml 58 62 58 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 257 261 257 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 696 703 696 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 1154 1157 1154 1157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p &lt;</italic>
###xml 1182 1189 1182 1189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 1273 1276 1273 1276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p &lt;</italic>
###xml 1490 1497 1490 1497 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 1749 1752 1749 1752 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p =</italic>
###xml 1971 1974 1971 1974 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p =</italic>
###xml 2057 2064 2057 2064 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 343 351 <span type="species:ncbi:9606">patients</span>
We examined the frequencies of the three polymorphisms of EGFR in 556 resected lung cancers and corresponding non-malignant lung tissues from 336 East Asians, 213 individuals of Northern European descent, and seven of other ethnicities. We also studied the EGFR gene in 93 corresponding non-malignant lung tissue samples from European-descent patients from Italy and in peripheral blood mononuclear cells from 250 normal healthy US individuals enrolled in epidemiological studies including individuals of European descent, African-Americans, and Mexican-Americans. We sequenced the four exons (18-21) of the TK domain known to harbor activating mutations in tumors and examined the status of the CA-SSR1 alleles (presence of heterozygosity, repeat number of the alleles, and relative amplification of one allele) and allele-specific amplification of mutant tumors as determined by a standardized semiautomated method of microsatellite analysis. Variant forms of SNP -216 (G/T or T/T) and SNP -191 (C/A or A/A) (associated with higher protein production in experimental systems) were less frequent in East Asians than in individuals of other ethnicities (p < 0.001). Both alleles of CA-SSR1 were significantly longer in East Asians than in individuals of other ethnicities (p < 0.001). Expression studies using bronchial epithelial cultures demonstrated a trend towards increased mRNA expression in cultures having the variant SNP -216 G/T or T/T genotypes. Monoallelic amplification of the CA-SSR1 locus was present in 30.6% of the informative cases and occurred more often in individuals of East Asian ethnicity. AI was present in 44.4% (95% confidence interval: 34.1%-54.7%) of mutant tumors compared with 25.9% (20.6%-31.2%) of wild-type tumors (p = 0.002). The shorter allele in tumors with AI in East Asian individuals was selectively amplified (shorter allele dominant) more often in mutant tumors (75.0%, 61.6%-88.4%) than in wild-type tumors (43.5%, 31.8%-55.2%, p = 0.003). In addition, there was a strong positive association between AI ratios of CA-SSR1 alleles and AI of mutant alleles.
###end p 4
###begin title 5
Conclusions
###end title 5
###begin p 6
###xml 83 90 83 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 375 379 375 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 432 440 432 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1,</italic>
###xml 494 501 494 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 341 349 <span type="species:ncbi:9606">patients</span>
The three polymorphisms associated with increased EGFR protein production (shorter CA-SSR1 length and variant forms of SNPs -216 and -191) were found to be rare in East Asians as compared to other ethnicities, suggesting that the cells of East Asians may make relatively less intrinsic EGFR protein. Interestingly, especially in tumors from patients of East Asian ethnicity, EGFR mutations were found to favor the shorter allele of CA-SSR1, and selective amplification of the shorter allele of CA-SSR1 occurred frequently in tumors harboring a mutation. These distinct molecular events targeting the same allele would both be predicted to result in greater EGFR protein production and/or activity. Our findings may help explain to some of the ethnic differences observed in mutational frequencies and responses to TK inhibitors.
###end p 6
###begin p 7
###xml 58 62 58 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 207 215 <span type="species:ncbi:9606">patients</span>
Masaharu Nomura and colleagues examine the distribution ofEGFR polymorphisms in different populations and find differences that might explain different responses to tyrosine kinase inhibitors in lung cancer patients.
###end p 7
###begin title 8
Editors' Summary
###end title 8
###begin title 9
Background.
###end title 9
###begin p 10
###xml 210 218 <span type="species:ncbi:9606">patients</span>
Most cases of lung cancer-the leading cause of cancer deaths worldwide-are "non-small cell lung cancer" (NSCLC), which has a very low cure rate. Recently, however, "targeted" therapies have brought new hope to patients with NSCLC. Like all cancers, NSCLC occurs when cells begin to divide uncontrollably because of changes (mutations) in their genetic material. Chemotherapy drugs treat cancer by killing these rapidly dividing cells, but, because some normal tissues are sensitive to these agents, it is hard to kill the cancer completely without causing serious side effects. Targeted therapies specifically attack the changes in cancer cells that allow them to divide uncontrollably, so it might be possible to kill the cancer cells selectively without damaging normal tissues. Epidermal growth factor receptor (EGRF) was one of the first molecules for which a targeted therapy was developed. In normal cells, messenger proteins bind to EGFR and activate its "tyrosine kinase," an enzyme that sticks phosphate groups on tyrosine (an amino acid) in other proteins. These proteins then tell the cell to divide. Alterations to this signaling system drive the uncontrolled growth of some cancers, including NSCLC.
###end p 10
###begin title 11
Why Was This Study Done?
###end title 11
###begin p 12
###xml 417 421 417 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 787 791 787 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 960 964 960 964 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 151 159 <span type="species:ncbi:9606">patients</span>
###xml 800 806 <span type="species:ncbi:9606">people</span>
Molecules that inhibit the tyrosine kinase activity of EGFR (for example, gefitinib) dramatically shrink some NSCLCs, particularly those in East Asian patients. Tumors shrunk by tyrosine kinase inhibitors (TKIs) often (but not always) have mutations in EGFR's tyrosine kinase. However, not all tumors with these mutations respond to TKIs, and other genetic changes-for example, amplification (multiple copies) of the EGFR gene-also affect tumor responses to TKIs. It would be useful to know which genetic changes predict these responses when planning treatments for NSCLC and to understand why the frequency of these changes varies between ethnic groups. In this study, the researchers have examined three polymorphisms-differences in DNA sequences that occur between individuals-in the EGFR gene in people with and without NSCLC. In addition, they have looked for associations between these polymorphisms, which are present in every cell of the body, and the EGFR gene mutations and allelic imbalances (genes occur in pairs but amplification or loss of one copy, or allele, often causes allelic imbalance in tumors) that occur in NSCLCs.
###end p 12
###begin title 13
What Did the Researchers Do and Find?
###end title 13
###begin p 14
###xml 41 45 41 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 100 108 100 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1,</italic>
###xml 217 221 217 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 612 619 612 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 757 761 757 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 991 995 991 995 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 509 515 <span type="species:ncbi:9606">people</span>
The researchers measured how often three EGFR polymorphisms (the length of a repeat sequence called CA-SSR1, and two single nucleotide variations [SNPs])-all of which probably affect how much protein is made from the EGFR gene-occurred in normal tissue and NSCLC tissue from East Asians and individuals of European descent. They also looked for mutations in the EGFR tyrosine kinase and allelic imbalance in the tumors, and then determined which genetic variations and alterations tended to occur together in people with the same ethnicity. Among many associations, the researchers found that shorter alleles of CA-SSR1 and the minor forms of the two SNPs occurred less often in East Asians than in individuals of European descent. They also confirmed that EGFR kinase mutations were more common in NSCLCs in East Asians than in European-descent individuals. Furthermore, mutations occurred more often in tumors with allelic imbalance, and in tumors where there was allelic imbalance and an EGFR mutation, the mutant allele was amplified more often than the wild-type allele.
###end p 14
###begin title 15
What Do These Findings Mean?
###end title 15
###begin p 16
###xml 264 268 264 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 540 544 540 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 764 768 764 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 304 310 <span type="species:ncbi:9606">people</span>
###xml 362 368 <span type="species:ncbi:9606">people</span>
###xml 1053 1061 <span type="species:ncbi:9606">patients</span>
The researchers use these associations between gene variants and tumor-associated alterations to propose a model to explain the ethnic differences in mutational frequencies and responses to TKIs seen in NSCLC. They suggest that because of the polymorphisms in the EGFR gene commonly seen in East Asians, people from this ethnic group make less EGFR protein than people from other ethnic groups. This would explain why, if a threshold level of EGFR is needed to drive cells towards malignancy, East Asians have a high frequency of amplified EGFR tyrosine kinase mutations in their tumors-mutation followed by amplification would be needed to activate EGFR signaling. This model, though speculative, helps to explain some clinical findings, such as the frequency of EGFR mutations and of TKI sensitivity in NSCLCs in East Asians. Further studies of this type in different ethnic groups and in different tumors, as well as with other genes for which targeted therapies are available, should help oncologists provide personalized cancer therapies for their patients.
###end p 16
###begin title 17
Additional Information.
###end title 17
###begin p 18
Please access these Web sites via the online version of this summary at .
###end p 18
###begin p 19
###xml 57 65 <span type="species:ncbi:9606">patients</span>
US National Cancer Institute information on  and on  for patients and professionals
###end p 19
###begin p 20
 on NSCLC
###end p 20
###begin p 21
###xml 5 13 <span type="species:ncbi:9606">patients</span>
 for patients about all aspects of lung cancer, including treatment with TKIs
###end p 21
###begin p 22
Wikipedia pages on , , and  (note that Wikipedia is a free online encyclopedia that anyone can edit)
###end p 22
###begin title 23
Introduction
###end title 23
###begin p 24
###xml 0 32 0 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Epidermal growth factor receptor</italic>
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR,</italic>
###xml 54 59 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERBB1</italic>
###xml 76 80 76 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERBB</italic>
###xml 206 207 206 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b001">1</xref>
###xml 208 209 208 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b003">3</xref>
###xml 374 375 374 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b004">4</xref>
###xml 376 377 376 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b005">5</xref>
###xml 533 534 533 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b006">6</xref>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b010">10</xref>
###xml 878 882 878 882 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 975 977 975 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b011">11</xref>
###xml 978 980 978 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b012">12</xref>
Epidermal growth factor receptor (EGFR, also known as ERBB1) belongs to the ERBB gene family of receptor tyrosine kinases (TKs), and is a major regulator of several distinct and diverse signaling pathways [1-3]. It is frequently overexpressed in many malignancies including non-small cell lung cancer (NSCLC), and overexpression may be associated with a negative prognosis [4,5]. A recent finding that mutations of the gene in lung cancers predict, somewhat imprecisely, response to TK inhibitors (TKIs) has generated much interest [6-10]. Mutations are limited to the first four exons of the TK domain, and occur more often in individuals with adenocarcinoma histology, East Asian origin, female gender, and never smoker status. However, exceptions exist to the correlation between mutation status and response to TKIs, suggesting that other factors may play a role. Recently, EGFR amplification has been identified as a further factor that may predict response to therapy [11,12]. Experimental evidence indicates that polymorphisms of the gene may also regulate protein expression.
###end p 24
###begin p 25
###xml 0 37 0 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA simple sequence repeat 1 (CA-SSR1)</italic>
###xml 168 172 168 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b013">13</xref>
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b014">14</xref>
###xml 279 286 279 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 418 420 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b015">15</xref>
###xml 486 493 486 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 530 534 530 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 645 647 645 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b013">13</xref>
###xml 648 650 648 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b014">14</xref>
CA simple sequence repeat 1 (CA-SSR1) is a highly polymorphic locus containing 14-21 CA dinucleotide repeats and is located at the 5' end of the long intron one of the EGFR gene, lying upstream and in close proximity to a second enhancer [13,14]. The allele size distribution of CA-SSR1 demonstrates ethnic differences, with East Asians having longer repeats than individuals of European descent or African-Americans [15]. By interacting with the second or downstream enhancer, a lower CA-SSR1 repeat number was found to modulate EGFR transcription in vivo and in vitro, and to be correlated with increased transcription and protein expression [13,14].
###end p 25
###begin p 26
###xml 25 32 25 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 51 55 51 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b016">16</xref>
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b017">17</xref>
###xml 158 165 158 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 264 268 264 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 383 385 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b018">18</xref>
###xml 445 452 445 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 581 583 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b019">19</xref>
###xml 413 421 <span type="species:ncbi:9606">patients</span>
The relationship between CA-SSR1 repeat length and EGFR overexpression has been extensively studied in breast cancers [16,17]. Localized amplification of the CA-SSR1 repeat, usually limited to the shorter allele, occurs frequently in breast cancers, is related to EGFR expression, and demonstrates a field effect, indicating that it is an early event during multistage pathogenesis [18]. In head and neck cancer, patients with a lower number of CA-SSR1 repeats (total of both alleles < 35 repeats) had a statistically significantly increased likelihood of responding to erlotinib [19].
###end p 26
###begin p 27
###xml 15 23 15 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1,</italic>
###xml 164 168 164 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 414 418 414 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 438 440 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b020">20</xref>
###xml 570 572 570 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b021">21</xref>
###xml 618 622 618 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 694 696 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b022">22</xref>
###xml 831 833 831 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b021">21</xref>
In addition to CA-SSR1, two kinds of single nucleotide polymorphisms (SNPs) in the promoter region may correlate with increased promoter activity and expression of EGFR mRNA. One of the SNPs is located -216 bp upstream from the initiator ATG (adenine as +1), and the change of nucleoside is guanine to thymine. This is an important binding site for the transcription factor SP1 that is necessary for activation of EGFR promoter activity [20]. The variant forms, -216 G/T or T/T, are more frequent in individuals of European descent and African-Americans than in Asians [21]. The other SNP, -191 C/C, is located in the EGFR promoter region near one of four transcription regions (-214 to -200) [22]. This SNP may also be associated with increased protein expression, and the minor forms, -191 C/A or A/A are also rare among Asians [21].
###end p 27
###begin p 28
###xml 193 200 193 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 261 268 261 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 349 353 349 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
###xml 216 224 <span type="species:ncbi:9606">patients</span>
###xml 318 326 <span type="species:ncbi:9606">patients</span>
For the reasons discussed above, we investigated the distribution of these SNPs in lung cancer patients and healthy individuals of various ethnicities, the length and allelic imbalance (AI) of CA-SSR1 in lung cancer patients, and the relationship between AI of CA-SSR1 and allele-specific amplification in lung cancer patients with mutations of the EGFR gene.
###end p 28
###begin title 29
Methods
###end title 29
###begin p 30
###xml 128 135 128 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040125-t001">Table 1</xref>
Because of the multiple, complex studies performed in this report, we summarize the salient investigations and their results in Table 1.
###end p 30
###begin title 31
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Bronchial Epithelial Cell and Lung Cancer Cell Lines
###end title 31
###begin p 32
###xml 186 187 186 187 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 132 138 <span type="species:ncbi:9913">bovine</span>
All cancer cell lines were cultured in RPMI 1640 (Life Technologies, Rockville, Maryland, United States) supplemented with 5% fetal bovine serum and incubated in humidified air and 5% CO2 at 37 degreesC. Most cell lines were established by us at one of two locations. The prefix NCI indicates cell lines established at the National Cancer Institute, and the prefix HCC indicates cell lines established at the Hamon Center for Therapeutic Oncology Research of the University of Texas Southwestern Medical Center.
###end p 32
###begin p 33
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b023">23</xref>
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b024">24</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human bronchial epithelial cells (HBECs) from healthy individuals or those with lung cancer were immortalized and cultured by us as previously described [23,24]. The cells were cultured in K-SFM medium (Life Technologies) and included 5 ng/ml EGF.
###end p 33
###begin title 34
Clinical Samples
###end title 34
###begin p 35
###xml 74 77 74 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n =</italic>
###xml 115 118 115 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n =</italic>
###xml 156 159 156 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n =</italic>
###xml 196 199 196 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n =</italic>
A total of 556 samples of primary lung cancers including adenocarcinomas (n = 345, 62%), squamous cell carcinomas (n = 182, 33%), adenosquamous carcinomas (n = 16, 3%), and large cell carcinomas (n = 10, 2%) were obtained from four countries, the US, Australia, Japan, and Taiwan, and included 336 (60%) tumors from East Asians and 220 (40%) from other ethnicities (97% of whom were of European descent). None of the cases had prior treatment with TKIs. Samples of tumor containing relatively high percentages of tumor (>70%) were selected and analyzed without microdissection.
###end p 35
###begin p 36
###xml 311 314 311 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n =</italic>
###xml 339 342 339 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n =</italic>
###xml 371 374 371 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n =</italic>
###xml 489 496 489 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040125-t002">Table 2</xref>
###xml 164 172 <span type="species:ncbi:9606">patients</span>
Corresponding non-malignant lung tissues were available from 450 of the samples. We also obtained 93 DNA samples from non-malignant lung tissue of European-descent patients with lung cancer in Italy and 250 DNA samples of peripheral blood mononuclear cells (PBMCs) from healthy individuals of European descent (n = 75), African-Americans (n = 75), and Mexican-Americans (n = 100) enrolled in ongoing epidemiological studies in the US for investigation of frequencies of the polymorphisms (Table 2). Institutional Review Board permission and informed consent were obtained at each collection site.
###end p 36
###begin title 37
DNA Extraction
###end title 37
###begin p 38
###xml 236 238 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b025">25</xref>
Genomic DNA was isolated from cell lines, frozen primary tumors, and non-malignant tissues by digestion with 100 mug/ml proteinase K (Life Technologies) followed by standard phenol-chloroform (1:1) extraction and ethanol precipitation [25].
###end p 38
###begin title 39
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
EGFR Gene Mutations
###end title 39
###begin p 40
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 106 107 106 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b009">9</xref>
###xml 164 168 164 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 549 550 549 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b009">9</xref>
Details about EGFR mutation types and methodologies for mutation detection have been published elsewhere [9]. Briefly, we sequenced exons 18-21 of the TK domain of EGFR in tumor and corresponding non-malignant tissues. The overall frequency of mutation was 20%, and there were three kinds of mutations, in-frame deletions in exon 19, missense mutations (predominantly mutation L858R in exon 21, but also in exons 18 or 20), and in-frame duplications/insertions of one to three codons in exon 20. The resistance-associated T790M mutation in exon 20 [9] was not detected in any tumor.
###end p 40
###begin title 41
###xml 12 16 12 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
Analysis of EGFR Polymorphic Sites
###end title 41
###begin p 42
###xml 78 82 78 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b021">21</xref>
We sequenced genomic DNA encompassing the SNP sites in the promoter region of EGFR -216 and -191 as described previously [21], using a single PCR reaction.
###end p 42
###begin p 43
###xml 550 551 549 550 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
The CA-repeat-containing region of intron one was amplified by PCR. The sequences of the primers were 5'-CCA ACC AAA ATA TTA AAC CTG TCT T-3' (forward) and 5'-CTT GAA CCA GGG ACA GCA AT-3' (reverse). For analysis of repeat allele lengths and relative ratios, instrumentation and reagents from Applied Biosystems (Foster City, California, United States) were utilized. The reverse primer was labeled with TAMRA fluorescent dye (6-FAM) at the 5' end. The 25-mul PCR reaction mixture contained 100 ng of genomic DNA, 10x PCR buffer containing 15 mM MgCl2, 2 mM of each dNTP, 10 pmol of each primer, and 1.25 units of HotStart Taq DNA polymerase (Qiagen, Valencia, California, United States). After an initial denaturalization step at 95 degreesC for 12 min, samples were cycled 35 times as follows: 94 degreesC for 30 s, 60 degreesC for 30 s, and 72 degreesC for 30 s. The final extension was at 72 degreesC for 20 min. The size of the products (about 80 bp) was confirmed by electrophoresis on 2% agarose gels. After PCR, 1 mul of the product plus 0.5 mul of Genescan 500 ROX molecular weight standard were denatured in 12 mul of Hi-Di Formamide (Applied Biosystems) and separated with a Prism Genetic Analyzer and analyzed by Gene Scan Analysis software 3.1 (Applied Biosystems).
###end p 43
###begin p 44
###xml 213 221 213 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040125-g001">Figure 1</xref>
###xml 275 282 275 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
Examination of the resultant traces demonstrated that biallelic (heterozygous) samples showed two sets of waves and two peaks, while the monoallelic (homozygous) samples showed a single set of waves and one peak (Figure 1). The highest peak reflects the repeat number of the CA-SSR1 allele as determined by the size marker, while the preceding waves (stutter bands) represent PCR-induced artifacts. In samples without AI the shorter peak appears artificially larger as a result of preferential PCR amplification. In non-malignant lung tissue the alleles were presumed to be of equal size, and their ratios were used as a correction factor for this artificial discrepancy.
###end p 44
###begin p 45
###xml 375 377 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b026">26</xref>
The degree of the amplification of each allele was indicated by the area under the peak as determined by software provided by the instrument's manufacturer. The relative ratios (AI ratios), termed LOH score in previous reports, of the two peaks (shorter peak area under the curve to longer peak area under the curve) in tumor samples were calculated as previously described [26]. The AI ratio was calculated thus: AI ratio = (T1 x N2)/(T2 x N1), where T indicates tumor, N indicates normal, 1 indicates the area under the peak for the shorter allele, and 2 indicates the area under the peak for the longer allele.
###end p 45
###begin p 46
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b026">26</xref>
###xml 918 926 <span type="species:ncbi:9606">patients</span>
As either peak could be increased in relative size, AI cases were divided into shorter allele dominant (SAD) or longer allele dominant (LAD) cases. We used the definitions of these two categories as determined previously [26]. SAD cases are defined as cases in which the adjusted AI ratio was greater than 1.27, and LAD cases were those in which the adjusted AI ratio was less than 0.79. For LAD cases, the formula results in ratio values less than unity. Therefore, the ratio was inverted for LAD cases, allowing the AI ratios to reflect the relative size of the longer allele, irrespective of which allele was increased in relative size. We confirmed the previous finding that the ratios of the areas under the curve for the two alleles in constitutional DNA on repeat testing or from different individuals are relatively constant. From an analysis of constitutional DNA from over 500 healthy individuals and cancer patients, we determined that the mean ratio of the two alleles in non-malignant tissues was 1.3, resulting from artificial preferential amplification of the shorter allele (data not shown). For tumor samples lacking corresponding non-malignant tissue, the AI was determined by the formula AI ratio = T1/(T2 x 1.3).
###end p 46
###begin p 47
###xml 537 544 537 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
The primers for investigation of selective amplification of the mutant or wild-type (WT) allele of exon 19 in-frame deletions and the exon 21 point mutation L858R were designed as follows: 5'-TCA CAA TTG CCA GTT AAC GTC T-3' (forward) and 5'-CAG CAA AGC AGA AAC TCA CAT C-3' (reverse) for exon 19, and 5'-ATG AAC TAC TTG GAG GAC CGT C-3' (forward) and 5'-TGC CTC CTT CTG CAT GGT ATT C-3' (reverse) for exon 21. Each forward primer was labeled with TAMRA fluorescent dye (6-FAM) at the 5' end. The conditions for PCR were the same as for CA-SSR1 except for the annealing temperature (57 degreesC for exon 19 and 61 degreesC for exon 21). The PCR products of exon 21 were cut by the restriction enzyme Sau96I (New England BioLabs, Ipswich, Massachusetts, United States) and analyzed. The size of each product (about 142 bp for mutant alleles of exon 19, 158 bp for the WT allele of exon 19, 100 bp for mutant the allele of exon 21, and 150 bp for the WT allele of exon 21) was also confirmed by electrophoresis in 2% agarose gels.
###end p 47
###begin p 48
The ratio (mutant allele/WT allele) to define amplification of each mutant allele, exon 19 in-frame deletion or the L858R point mutation, was determined by ROC (receiver operating characteristics) curves using the definitive value of AI, 1.27 (data not shown). The definitive ratios for exon 19 and 21 were 0.82 (sensitivity 70%, specificity 68%) and 0.2 (sensitivity 90%, specificity 90%), respectively, and the combined definitive ratio was 0.47 (sensitivity 70%, specificity 61%). We used these ratios as cut-off values to determine whether the mutant allele was amplified. Because of the presence of various amounts of non-malignant cells in the tumor samples, amplifications of the WT allele could not be determined with certainty.
###end p 48
###begin title 49
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
Real-Time PCR for the Expression of EGFR mRNA
###end title 49
###begin p 50
###xml 335 339 334 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACTB</italic>
###xml 516 520 515 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 629 633 628 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACTB</italic>
###xml 655 659 654 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 664 668 663 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACTB</italic>
###xml 684 692 683 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040125-g002">Figure 2</xref>
###xml 734 743 733 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR:ACTB</italic>
cDNA was prepared by reverse transcription of 2 mug of RNA from cell lines using SuperScript II reverse transcriptase according to the manufacturer's protocol (Invitrogen, Carlsbad, California, United States). Real-time PCR was performed with the Sybro (SYBR) Green I method using Power SYBR Green PCR Master Mix (Applied Biosystems). ACTB cDNA was used as an internal control. Primer sequences were as follows: 5'-ATA GTC GCC CAA AGT TCC GTG AGT-3' (forward) and 5'-ACC ACG TCG TCC ATG TCT TCT TCA-3' (reverse) for EGFR and 5'-AGT CCT GTG GCA TCC ACG AAA CTA-3' (forward) and 5'-ACT GTG TTG GCG TAC AGG TCT TTG-3' (reverse) for ACTB. Standard curves for EGFR and ACTB were obtained (Figure 2A), and the relative expression ratios of EGFR:ACTB were calculated.
###end p 50
###begin title 51
Statistical Analyses
###end title 51
###begin p 52
###xml 533 540 533 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 568 569 568 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 688 695 688 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 891 899 891 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040125-t003">Tables 3</xref>
###xml 900 901 900 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040125-t006">6</xref>
###xml 917 924 917 924 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 971 979 971 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040125-g003">Figure 3</xref>
###xml 1437 1439 1437 1439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p-</italic>
###xml 1510 1512 1510 1512 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p-</italic>
We used the Chi-square test (testing the null hypothesis of equal distributions across study groups) to compare the distributions across study groups when outcomes were discrete such as genotypes of the SNP or SAD frequencies. When events were rare, e.g., where the expected cell counts were less than five, Fisher's exact test was used instead for comparisons. We also used Chi-square for an independent test for the assessment of each ethnic group using the Hardy-Weinberg equilibrium model. When outcomes were continuous, such as CA-SSR1 repeat numbers, two-sample t-test and analysis of variance were used. In order to control for potential confounding bias in comparisons of SNP and CA-SSR1 distributions, the multivariate logistic and general linear regression models were used with certain clinicopathological factors such as age, gender, smoking status, and histology as covariates (Tables 3-6). AI ratios of CA-SSR1 plotted against mutant/WT ratios are shown in Figure 3 with the fitted regression lines. The associations between AI ratios and mutant/WT ratios were tested using Pearson's correlation for exon 19, exon 21, and both combined. To be conservative in case of small sample size and extreme values, the nonparametric Wilcoxon rank sum test was used to compare mutant/WT ratios for those with and without SAD. In this paper, all statistical tests and 95% confidence intervals are two-sided. Because of multiple tests, p-values less than 0.01 were judged to be statistically significant, and p-values less than 0.05 were judged as moderately significant. Both positive and negative results are reported in the tables and in the text.
###end p 52
###begin title 53
Results
###end title 53
###begin p 54
###xml 132 139 132 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040125-t001">Table 1</xref>
Because of the complex nature of the findings and their interrelationships, a tabular summary of our major findings is presented in Table 1.
###end p 54
###begin title 55
Ethnic Differences in Distribution of Polymorphisms
###end title 55
###begin p 56
###xml 132 136 132 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 151 158 151 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 269 276 269 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040125-t002">Table 2</xref>
###xml 484 487 484 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p =</italic>
###xml 495 505 495 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040125-sd005">Dataset S1</xref>
###xml 816 819 816 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p &lt;</italic>
###xml 984 991 984 991 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 1331 1334 1331 1334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p =</italic>
###xml 1491 1501 1491 1501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040125-sd005">Dataset S1</xref>
###xml 244 252 <span type="species:ncbi:9606">patients</span>
We examined ethnic differences in the distribution of the minor alleles of the two SNPs -216 and -191 in the promoter region of the EGFR gene and mean CA-SSR1 repeat numbers. A summary of the samples studied from healthy individuals and cancer patients is presented in Table 2. For healthy US individuals, the frequencies of the -216 genotypes showed a borderline statistically significant difference between individuals of European descent, African-Americans, and Mexican-Americans (p = 0.08) (Dataset S1). The G/G genotype was present in 46.7% (95% confidence interval: 35.4%-58.0%) of individuals of European descent compared to 60% (48.9%-71.1%) and 63% (53.5%-72.5%) of African-Americans and Mexican-Americans, respectively. The frequencies of the minor forms of the -191 polymorphism were significantly lower (p < 0.001) in African-Americans (10.7%, 3.7%-17.7%) than in individuals of European descent (36%, 25.1%-46.9%) and Mexican-Americans (43%, 33.3%-52.7%). Also, the mean CA-SSR1 repeat number was significantly shorter in individuals of European descent (for the shorter, longer, or combined allele lengths) than in African-Americans and Mexican-Americans (combined allele length for individuals of European descent, 35.3, 34.7-35.9, for African-Americans, 36.2, 35.6-36.8, and for Mexican-Americans, 36.8, 36.3-37.3; p = 0.001). The differences between African-Americans and Mexican-Americans were relatively modest and only reached significance for the shorter allele length (Dataset S1).
###end p 56
###begin p 57
###xml 250 257 250 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040125-t003">Table 3</xref>
###xml 262 272 262 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040125-sd005">Dataset S1</xref>
###xml 412 415 412 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p =</italic>
###xml 561 564 561 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p =</italic>
###xml 588 595 588 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 793 796 793 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p =</italic>
###xml 837 844 837 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040125-t004">Table 4</xref>
###xml 846 856 846 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040125-sd005">Dataset S1</xref>
###xml 385 393 <span type="species:ncbi:9606">patients</span>
###xml 539 547 <span type="species:ncbi:9606">patients</span>
###xml 771 779 <span type="species:ncbi:9606">patients</span>
###xml 931 939 <span type="species:ncbi:9606">patients</span>
###xml 1060 1068 <span type="species:ncbi:9606">patients</span>
Among US European-descent individuals in this study, there were no significant differences in the frequency of the three polymorphisms between the healthy individuals (DNA from PBMCs) and those with NSCLC (DNA from non-malignant tissue). As shown in Table 3 and Dataset S1, the -216 G/G form was present in 46.7% (35.4%-58.0%) of the healthy individuals and 39.7% (30.8%-47.4%) of the patients with lung cancer (p = 0.321), and the -191 C/C genotype was present in 64% (53.1%-74.9%) of the healthy individuals and 63% (54.8%-71.2%) of the patients with cancer (p = 0.941). Also, the mean CA-SSR1 repeat numbers for the short allele, long allele, and combined alleles of healthy European-descent individuals were not significantly different from those of European-descent patients with cancer (p = 0.492, 0.604, and 0.495, respectively) (Table 4; Dataset S1). These data permitted us to presume that the polymorphism frequencies in patients with lung cancer follow the pattern of the general population, and we can combine the data from healthy individuals and patients with NSCLC for individuals of European descent, which is the dominant ethnicity of the US, Italy, and Australia populations in this study. Furthermore, no significant differences were observed in this study for the frequencies of all three polymorphisms between individuals of European descent in the US versus in Italy, nor between East Asians in Japan versus in Taiwan (data not shown). Thus, we pooled the data from these two groups and labeled them as "individuals of European descent" and "East Asians," which were then used for further analyses.
###end p 57
###begin p 58
###xml 143 146 143 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p &lt;</italic>
###xml 395 398 395 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p &lt;</italic>
###xml 419 426 419 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040125-t003">Table 3</xref>
###xml 441 448 441 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040125-t004">Table 4</xref>
###xml 476 483 476 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 600 603 600 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p &lt;</italic>
Comparing individuals of European descent and East Asians, the frequency of the minor forms of the -216 polymorphism was significantly higher (p < 0.001) in individuals of European descent (60.3%, 54.8%-65.8%) than in East Asians (6.6%, 3.9%-9.3%). This was also true for the minor forms of the -191 polymorphism (individuals of European descent, 37.0%, 31.6%-42.4%; East Asians, 0.6%, 0%-1.4%; p < 0.001), as shown in Table 3. In addition, Table 4 shows that both alleles of CA-SSR1 (and the combined allele length) were significantly shorter in individuals of European descent than in East Asians (p < 0.001). The comparisons were controlled for potential confounders such as gender, age, and smoking.
###end p 58
###begin title 59
###xml 21 28 21 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
Relationship between CA-SSR1 Allele Lengths and SNPs
###end title 59
###begin p 60
###xml 65 71 65 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR</italic>
###xml 106 113 106 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040125-t005">Table 5</xref>
###xml 234 240 234 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR</italic>
We first examined the concordance of the SNP -216, SNP -191, and CA-SSR repeat polymorphisms. As shown in Table 5, individuals who were homo- or heterozygous for the variant forms of SNP -216 (G/T or T/T) had significantly lower mean CA-SSR repeat numbers in short, long, and combined allele lengths than those who were homozygous for the common form -216 G/G after adjustment for ethnicity. In similar comparisons for the variant forms of SNP -191, there was significant concordance with the longer and combined allele lengths, but not for the shorter allele.
###end p 60
###begin p 61
###xml 153 160 153 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 381 388 381 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040125-t006">Table 6</xref>
###xml 1140 1150 1140 1150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040125-sd006">Dataset S2</xref>
We next investigated the relationship between the combined allele length and the SNPs for different ethnicities. For convenience, since the overall mean CA-SSR1 repeat number for shorter and longer allele combined was 36, we dichotomized the combined allele length as "longer" for those with greater than 36 repeats and as "shorter" for those with 36 repeats or fewer. As shown in Table 6, the frequency of the "shorter" combined allele was significantly higher in individuals with the minor forms of -216 (East Asians, 72.7%, 54.1%-91.3%; individuals of European descent, 81.2%, 76.1%-86.3%) than in those with the common form (East Asians, 36.6%, 30.9%-41.7%; individuals of European descent, 53.7%, 45.8%-61.6%). A similar pattern for SNP -191 was noted in East Asians but not in individuals of European descent. Also, for individuals carrying both variant genotypes of the two SNPs, the frequency of the "shorter" combined allele was observed to be higher than in those with the common forms of the SNPs in both individuals of European descent and East Asians, although the difference was statistically significant only in East Asians (Dataset S2).
###end p 61
###begin title 62
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
Relationship between EGFR Expression and the -216 Polymorphism
###end title 62
###begin p 63
###xml 216 223 216 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 651 652 651 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 666 667 666 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 738 742 738 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 780 788 780 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040125-g002">Figure 2</xref>
###xml 794 795 794 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040125-g002">2</xref>
The polymorphism genotype of the 11 HBEC cultures was determined as previously described. The lines, derived from American individuals of European descent, showed little variation in the repeat length of the shorter CA-SSR1 allele (mean length 16.2, range 16-17). Similarly, for the -191 polymorphism, ten of the cases had the common C/C genotype and only one case demonstrated the C/A genotype. Thus, we were unable to study the effects of these two polymorphisms on gene expression in the HBEC cultures. However, for the -216 polymorphism, four of the cases had the common form, G/G, while the remaining seven cases expressed the variant forms G/T (n = 5) or T/T (n = 2). Thus, we limited our examination of the relationship of SNPs to EGFR expression to the -216 polymorphism (Figure 2B and 2C).
###end p 63
###begin p 64
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACTB</italic>
###xml 33 37 33 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 105 113 105 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040125-g002">Figure 2</xref>
###xml 376 380 376 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 604 612 604 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040125-g002">Figure 2</xref>
###xml 787 791 787 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 994 996 994 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b027">27</xref>
###xml 997 999 997 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b028">28</xref>
The standard curves for ACTB and EGFR mRNA expression were straight lines nearly parallel to each other (Figure 2A), permitting us to use the expression ratio of these two genes for comparisons. To further validate our assays, we determined the ratios for the HBECs as well as for eight NSCLC cell lines having the WT form and for seven cell lines having a mutant form of the EGFR gene. As expression in normal epithelial cells is low or not detectable in the absence of ligand, the HBECs were cultured in EGF-containing medium (5 ng/ml). Expression in the HBECs was relatively low, with a narrow range (Figure 2B). The lung cancer lines, grown in the absence of added ligand, showed considerable variability of expression. Four WT lines had low expression, while four lines, all having EGFR copy number of four or greater, had considerably higher expression levels. Four of the mutant lines, all highly amplified for copy number and lacking the secondary resistance-associated T790M mutation [27,28], had high expression ratios. However three mutant lines had low expression ratios. Two of these lines had the secondary T790M mutation as well as an activating mutation, while the third line had a relatively low copy number.
###end p 64
###begin p 65
###xml 104 112 104 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040125-g002">Figure 2</xref>
While the range of expression in the HBECs was modest, we correlated expression with the -216 genotype (Figure 2C). The four lines having the G/G phenotype had a mean expression ratio of 1.0 (range 0.5-1.3). The seven lines having one of the two variant forms had a mean expression ratio of 1.2 (range 1.0-1.7). The two lines homozygous for the variant form T/T were among the three highest expressing lines. While these differences were not significant, they may represent a trend towards higher expression being associated with the variant forms.
###end p 65
###begin p 66
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 53 57 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACTB</italic>
###xml 155 159 155 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 231 234 231 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n =</italic>
###xml 321 324 321 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n =</italic>
###xml 329 337 329 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040125-g002">Figure 2</xref>
###xml 368 375 368 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 638 645 638 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
The range of relative expression of EGFR compared to ACTB of lung cancer cell lines was variable. The two high values were observed in the cell lines with EGFR mutation. The mean value of cell lines having the common SNP -216 G/G (n = 4) was 0.97, compared to 1.24 for the lines with the minor forms SNP -216 G/T or T/T (n = 7) (Figure 2C). The range of the number of CA-SSR1 repeats in the cell lines, all from individuals of European descent, was from 16 to 17 for the shorter allele, 16 to 19 for the longer allele, and 32 to 38 for the combined length. The highest value was observed in the group with the shortest combined number of CA-SSR1 repeats (32) and one of the minor SNP -216 forms.
###end p 66
###begin title 67
The Relationship between Polymorphisms and Survival
###end title 67
###begin p 68
###xml 74 80 74 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR</italic>
###xml 132 141 132 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040125-sg001">Figure S1</xref>
###xml 341 348 341 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 704 707 704 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p =</italic>
###xml 830 834 830 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 1019 1021 1019 1021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b029">29</xref>
###xml 1045 1052 1045 1052 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 106 113 <span type="species:ncbi:9606">patient</span>
###xml 744 752 <span type="species:ncbi:9606">patients</span>
###xml 1108 1115 <span type="species:ncbi:9606">patient</span>
We also investigated the relationship between the SNP -216, SNP -191, and CA-SSR repeat polymorphisms and patient overall survival (Figure S1). We did not observe a relationship between survival and either SNP form or any combination of SNP forms after adjusting for age, gender, ethnicity, smoking, and histology. For the shorter allele of CA-SSR1 in the tumor cases, the mean length was 17.5. We divided the cases into those having shorter alleles, with mean lengths of 17 or fewer repeats, and those having a mean length of 18 or more repeats. We found that cases having a mean length of 18 or more repeats had improved survival compared to those having shorter allele lengths of 17 or fewer repeats (p = 0.017). These findings suggest that patients (in the absence of TKI therapy) whose tumor cells are predicted to make less EGFR protein have an improved survival compared to those whose cells are predicted to have higher intrinsic protein production. Similar data have been reported recently from another group [29]. For cases with AI of CA-SSR1 (see below) or of the mutant allele, no differences in patient survival were noted (data not shown).
###end p 68
###begin title 69
###xml 10 17 10 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
AI of the CA-SSR1 Alleles
###end title 69
###begin p 70
###xml 94 102 94 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040125-g001">Figure 1</xref>
###xml 165 172 165 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 608 615 608 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 734 736 734 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b016">16</xref>
###xml 737 739 737 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b026">26</xref>
###xml 1060 1061 1060 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1163 1164 1163 1164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1192 1195 1192 1195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n =</italic>
###xml 1283 1287 1283 1287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 1079 1087 <span type="species:ncbi:9606">patients</span>
The degree of amplification of each allele was reflected by the relative area under the peak (Figure 1), and the AI was determined by the ratio of shorter to longer CA-SSR1 alleles in informative cases where two alleles were of different length. Among 450 tumor cases where the corresponding non-malignant lung tissues were available, there was no difference in the presence of homo- or heterozygosity of allele length or in the repeat length of each allele between tumor and non-malignant tissues (data not shown). These findings permitted us to analyze all 556 cases using the tumor tissues alone. For the CA-SSR1 alleles, 376 (68%) of 556 cases were informative. The informative rate was similar to that in other previous studies [16,26]. However, in our study the informative rate was not consistent across ethnicities: there was an informative rate of 62.8 % (211/336) in East Asians and 75.0% (165/220) in other ethnicities. Of the 376 informative cases, we excluded cases with mutations other than deletions in exon 19 or the L858R mutation in exon 21 (n = 12) as well as patients of ethnicities other than East Asians and individuals of European descent (n = 5) and Asians in the US (n = 3). Of the remaining 356 NSCLC cases of East Asian or European descent, 263 had the WT EGFR gene and 95 had the mutations in exon 19 or exon 21.
###end p 70
###begin p 71
###xml 53 60 53 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 264 267 264 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p =</italic>
###xml 477 480 477 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p =</italic>
###xml 489 496 489 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040125-t007">Table 7</xref>
###xml 498 508 498 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040125-sd007">Dataset S3</xref>
For these 356 cases, we determined the ratios of the CA-SSR1 alleles as previously described in the Methods section. AI, defined by an allelic ratio greater than 1.27 or less than 0.79, was present in 109 (30.6 %) of the cases but was significantly more frequent (p = 0.002) in cases with mutant tumors (44.4%, 34.1%-54.7%) than in those with WT tumors (25.9%, 20.6%-31.2%), and in East Asians (35.6%, 29.0%-42.2%) than in individuals of European descent (23.8%, 17.0%-30.6%) (p = 0.019) (Table 7; Dataset S3).
###end p 71
###begin p 72
###xml 69 76 69 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040125-t008">Table 8</xref>
###xml 82 92 82 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040125-sd007">Dataset S3</xref>
###xml 288 291 288 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p =</italic>
###xml 473 481 <span type="species:ncbi:9606">patients</span>
The 109 cases with AI were also divided into SAD or LAD. As shown in Table 8 (and Dataset S3), the overall frequency of SAD was 60.3% (49.1%-71.5%) in East Asians and 44.4% (28.2%-60.6%) in individuals of European descent. Also, in East Asians the SAD frequency was significantly higher (p = 0.001) in tumors with the exon 19 or exon 21 mutation than in those without mutations (82.4%, 69.6%-95.2%, versus 41.0%, 25.6%-56.4%). This difference, however, was not observed in patients of European descent.
###end p 72
###begin title 73
AI of Mutant to WT Allele
###end title 73
###begin p 74
###xml 232 240 232 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040125-g004">Figure 4</xref>
###xml 342 349 342 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 594 601 594 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 847 851 835 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 872 873 860 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b009">9</xref>
###xml 1074 1081 1062 1069 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 1295 1302 1283 1290 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 1361 1368 1349 1356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 1445 1453 1433 1441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040125-g003">Figure 3</xref>
###xml 2007 2014 1995 2002 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
For cases with the deletions in exon 19 or the L858R mutation in exon 21, the AI of the mutant allele was determined by the mutant/WT allele ratio. A flow chart describing the process of case selection and exclusion is presented in Figure 4. These mutant cases gave us an opportunity to examine the association between AI in amplification of CA-SSR1 repeats and AI in the ratio of mutant to WT alleles. Specifically, we wished to determine, in cases having both forms of AI, whether the mutant form was selectively amplified in association with selective amplification of the shorter allele of CA-SSR1. As described in the Methods section, we devised methods to determine the ratios of mutant to WT alleles for the two most frequent mutations, deletions in exon 19 and the L858R mutation in exon 21, which together account for approximately85% of EGFR mutations in NSCLC [9]. Of the 109 cases with mutations (in exon 19 or L858R), sufficient DNA was available from 76. Of these 76 samples, 32 (42.1%) tumors had selective imbalance involving the mutant allele. The ratio of CA-SSR1 alleles was utilized to determine whether AI was present and, if present, which of the two alleles was preferentially overrepresented. Of these 32 samples having AI of the mutant allele, 26 (81.3%) also had AI of CA-SSR1. In addition, a positive correlation between AI ratios of CA-SSR1 and mutant/WT ratios was observed in tumors having either form of mutation (Figure 3). The linear correlation was tested using Pearson's correlation and found to be significant. However, because of the possibility that the observed strong correlation might be driven by extreme values given the small sample size of the available cases, we used a nonparametric test instead to compare mutant/WT ratios between those with SAD and those without. As expected, for all the mutations under study, the cases with SAD had higher mean mutant/WT ratios than those without SAD. These findings agreed with our hypothesis that in cases demonstrating CA-SSR1 imbalance, the mutant allele was more frequently increased in relative copy number compared to the WT allele.
###end p 74
###begin title 75
Discussion
###end title 75
###begin p 76
###xml 80 84 80 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 348 355 348 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 512 514 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b021">21</xref>
###xml 596 603 596 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 657 659 657 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b013">13</xref>
###xml 660 662 660 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b019">19</xref>
###xml 663 665 663 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b021">21</xref>
###xml 666 668 666 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b026">26</xref>
###xml 701 705 701 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 756 763 756 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 1725 1729 1725 1729 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 191 199 <span type="species:ncbi:9606">patients</span>
In this report we examined the frequency of three germline polymorphisms in the EGFR gene in healthy individuals of different ethnicities, and in non-malignant and malignant lung tissue from patients with NSCLC. We found ethnic-related differences in polymorphism frequencies consistent with previous reports, indicating that the shorter allele of CA-SSR1 and the minor forms of SNPs -191 (C/A or A/A) and -216 (G/T or T/T) are significantly less frequent in East Asians than in individuals of European descent [21]. In addition, we noted a relationship between the presence of the short form of CA-SSR1 and the minor forms of the SNPs. The published data [13,19,21,26] and our observations regarding EGFR mRNA expression in HBECs suggest that the shorter CA-SSR1 allele lengths and the variant forms of the -191 and -216 polymorphisms are associated with increased intrinsic gene expression. However, most of the data in the literature are from the results of transfection studies or tumor cell lines, and thus may not reflect the state of normal epithelial cells. As sections of non-malignant lung contain only a small minority of epithelial cells, a study of adjacent non-malignant lung tissues from resected cases or peripheral blood cells would not yield meaningful data. In an attempt to overcome these limitations, we studied 11 cultures of immortalized HBECs. These cultures show minimal genetic changes. In the presence of ligand stimulation, we demonstrated a trend for increased mRNA expression in lines having the SNP -216 G/T or T/T genotypes, consistent with published data. The published reports and our results are consistent with the hypothesis that cells of individuals of East Asian ethnicity express less EGFR protein constitutively than cells of individuals of other ethnicities. However, final experimental proof for this hypothesis is still lacking.
###end p 76
###begin p 77
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b012">12</xref>
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b030">30</xref>
###xml 278 282 278 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b011">11</xref>
###xml 370 372 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b031">31</xref>
###xml 429 436 429 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 611 613 611 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b032">32</xref>
###xml 851 853 851 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b012">12</xref>
Amplification of the EGFR gene is relatively common in lung and other cancers, and may be associated with mutations of the TK domain in lung cancers [12] or of the extracellular domain in glioblastomas [30]. Two recent reports describe a correlation between copy numbers of the EGFR gene as measured by fluorescence in situ hybridization (FISH) and response to TKIs [11,31]. In this study we used allelic size differences in the CA-SSR1 repeat polymorphism to determine AI of the gene. AI was observed in 30.2% of informative cases, a frequency comparable to increased copy number as detected by FISH analyses [32]. AI was significantly more frequent in East Asians and occurred nearly twice as frequently in mutant cases than in WT cases. A relationship between increased copy number by FISH analysis and mutation has also been described previously [12]. While there were no significant differences in the frequencies of either the shorter or longer allele being involved in the imbalance for all of the cases or for all of the mutant cases, in mutant cases arising in East Asians, the shorter allele was twice as likely to be preferentially amplified as the longer allele.
###end p 77
###begin p 78
###xml 481 488 481 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 724 731 724 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
Finally we determined whether the mutant allele was selectively amplified in tumors having both mutation and imbalance. For tumors having deletion mutations in exon 19 or the L858R point mutation in exon 21 (together accounting for 86.5% of all mutations) we devised methods for determining the ratio of mutant to WT alleles. Of 76 cases examined, 42.1% demonstrated imbalance of the mutant allele. This figure is consistent with our finding of an overall AI (from analysis of the CA-SSR1 alleles) percentage of 45.3% in mutant cases, and suggests that in mutation-containing tumors having AI, the mutant allele is the one that is usually amplified. Having found, by separate analyses in mutant cases, that both the shorter CA-SSR1 allele and the mutant allele were selectively amplified, we performed a correlation of these two forms of imbalance and demonstrated a strong positive association.
###end p 78
###begin p 79
###xml 131 138 131 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 200 204 200 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 287 294 287 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 386 390 386 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 517 521 517 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 616 620 616 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 954 961 954 961 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 1094 1102 1094 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040125-g005">Figure 5</xref>
###xml 1153 1160 1153 1160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 1487 1491 1487 1491 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 1579 1581 1579 1581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b033">33</xref>
###xml 1659 1663 1659 1663 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 1734 1736 1734 1736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040125-b012">12</xref>
Incorporation of our findings and previously published data form the basis of a hypothesis suggesting a close relationship between CA-SSR1 length, SNP -191 polymorphism, and SNP -216 polymorphism and EGFR gene amplification. As mentioned above, all three of these polymorphisms (shorter CA-SSR1 length and the variant forms of the two SNPs) are reported to be associated with increased EGFR production, and they were rarely observed in East Asians. These findings suggest that the cells of most East Asians make less EGFR protein than do the cells of individuals of other ethnicities. If a certain critical level of EGFR is required to drive the cell toward a malignant phenotype, mutations of the TK domain and autonomous activation of downstream signaling may target East Asians, the subgroup with possibly lower intrinsic protein production. Also, we found in East Asians (but not in individuals of European descent) that mutations target the shorter CA-SSR1 allele (suggestive of greater protein production) followed by allele-specific amplification of the mutant allele. As illustrated in Figure 5, three events target the same allele: (a) shorter CA-SSR1 repeat length, (b) activating mutation, and (c) selective amplification of the mutant allele. These interactions favor greater protein production in mutant tumors. A similar observation was made in glioblastomas, which frequently contain a mutation or splicing variant resulting in loss of much of the extracellular domain of EGFR. The variant form of the allele frequently demonstrated allele-specific amplification [33]. As previously mentioned, FISH technology has been used to demonstrate that EGFR amplification and mutation often, but not invariably, occur together [12].
###end p 79
###begin title 80
Conclusions
###end title 80
###begin p 81
###xml 83 90 83 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 394 398 394 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 451 459 451 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1,</italic>
###xml 513 520 513 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 360 368 <span type="species:ncbi:9606">patients</span>
The three polymorphisms associated with increased EGFR protein production (shorter CA-SSR1 length and the variant forms of SNPs -216 and -191) were found to be rare in East Asians as compared to individuals of other ethnicities, suggesting that the cells of East Asians may make relatively less intrinsic EGFR protein. Interestingly, especially in tumors from patients of East Asian ethnicity, EGFR mutations were found to favor the shorter allele of CA-SSR1, and selective amplification of the shorter allele of CA-SSR1 occurred frequently in tumors harboring a mutation. These distinct molecular events targeting the same allele would both be predicted to result in greater EGFR protein production and/or activity. These findings may reveal what underlies some of the ethnic differences observed in mutational frequencies and responses to TKIs.
###end p 81
###begin title 82
Supporting Information
###end title 82
###begin title 83
Translation into Japanese by Masaharu Nomura
###end title 83
###begin p 84
(27 KB DOC)
###end p 84
###begin p 85
Click here for additional data file.
###end p 85
###begin title 86
Translation into French by Masaharu Nomura
###end title 86
###begin p 87
(31 KB DOC)
###end p 87
###begin p 88
Click here for additional data file.
###end p 88
###begin title 89
Translation into German by Masaharu Nomura
###end title 89
###begin p 90
(31 KB DOC)
###end p 90
###begin p 91
Click here for additional data file.
###end p 91
###begin title 92
Translation into Spanish by Masaharu Nomura
###end title 92
###begin p 93
(31 KB DOC)
###end p 93
###begin p 94
Click here for additional data file.
###end p 94
###begin title 95
Ethnic Differences in Polymorphisms
###end title 95
###begin p 96
(37 KB DOC)
###end p 96
###begin p 97
Click here for additional data file.
###end p 97
###begin title 98
###xml 49 53 49 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
Relationship between the Three Polymorphisms and EGFR Mutations
###end title 98
###begin p 99
(55 KB DOC)
###end p 99
###begin p 100
Click here for additional data file.
###end p 100
###begin title 101
###xml 21 28 21 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
Mutations Target the CA-SSR1 Allele Having the Lower Number of Repeats
###end title 101
###begin p 102
(48 KB DOC)
###end p 102
###begin p 103
Click here for additional data file.
###end p 103
###begin title 104
###xml 79 86 79 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 17 25 <span type="species:ncbi:9606">Patients</span>
The Prognosis of Patients Based on the Average Length of the Shorter Allele of CA-SSR1
###end title 104
###begin p 105
###xml 62 69 62 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 28 36 <span type="species:ncbi:9606">patients</span>
###xml 236 244 <span type="species:ncbi:9606">patients</span>
Overall survival curves for patients having a short allele of CA-SSR1 under versus over the average length (17.5). Survival was not influenced by the minor forms of the -191 or -216 polymorphisms (data not shown). Note that none of the patients received TKI therapy.
###end p 105
###begin p 106
(86 KB PPT)
###end p 106
###begin p 107
Click here for additional data file.
###end p 107
###begin p 108
###xml 13 17 <span type="species:ncbi:156483">Mani</span>
We thank Dr. Mani Yegappan for his help with allele-specific assays. We also thank Dr. Mituso Sato, Dr. Luc Girard, and Mr. Sunny Zachariah for providing nucleic acids and HBEC lines.
###end p 108
###begin title 109
Abbreviations
###end title 109
###begin p 110
allelic imbalance
###end p 110
###begin p 111
CA simple sequence repeat 1
###end p 111
###begin p 112
epidermal growth factor receptor
###end p 112
###begin p 113
flourescence in situ hybridization
###end p 113
###begin p 114
###xml 0 5 <span type="species:ncbi:9606">human</span>
human bronchial epithelial cell
###end p 114
###begin p 115
longer allele dominant
###end p 115
###begin p 116
non-small cell lung cancer
###end p 116
###begin p 117
peripheral blood mononuclear cell
###end p 117
###begin p 118
short allele dominant
###end p 118
###begin p 119
single nucleotide polymorphism
###end p 119
###begin p 120
tyrosine kinase
###end p 120
###begin p 121
tyrosine kinase inhibitor
###end p 121
###begin p 122
wild-type
###end p 122
###begin title 123
References
###end title 123
###begin article-title 124
Tyrosine kinase inhibitors: Why does the current process of clinical development not apply to them?
###end article-title 124
###begin article-title 125
The ErbB receptors and their role in cancer progression
###end article-title 125
###begin article-title 126
The erbB family: Targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors
###end article-title 126
###begin article-title 127
###xml 0 18 0 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HER-2, EGFR, COX-2</italic>
HER-2, EGFR, COX-2 expression status correlated to microvessel density and survival in resected non-small cell lung cancer
###end article-title 127
###begin article-title 128
###xml 141 149 <span type="species:ncbi:9606">patients</span>
Cytogenetic abnormalities and overexpression of receptors for growth factors in normal bronchial epithelium and tumor samples of lung cancer patients
###end article-title 128
###begin article-title 129
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
###end article-title 129
###begin article-title 130
Cancer. A bull's eye for targeted lung cancer therapy
###end article-title 130
###begin article-title 131
Mutations and addiction to EGFR: The Achilles 'heal' of lung cancers?
###end article-title 131
###begin article-title 132
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
###end article-title 132
###begin article-title 133
EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
###end article-title 133
###begin article-title 134
Erlotinib in lung cancer-Molecular and clinical predictors of outcome
###end article-title 134
###begin article-title 135
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
###end article-title 135
###begin article-title 136
Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1
###end article-title 136
###begin article-title 137
Modulation of EGFR gene transcription by secondary structures, a polymorphic repetitive sequence and mutations-A link between genetics and epigenetics
###end article-title 137
###begin article-title 138
###xml 54 59 <span type="species:ncbi:9606">human</span>
Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism
###end article-title 138
###begin article-title 139
Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence-First results of an inter-ethnic breast cancer study
###end article-title 139
###begin article-title 140
Distinct amplification of an untranslated regulatory sequence in the egfr gene contributes to early steps in breast cancer development
###end article-title 140
###begin article-title 141
Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma
###end article-title 141
###begin article-title 142
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors
###end article-title 142
###begin article-title 143
###xml 113 118 <span type="species:ncbi:9606">human</span>
Structure and localization of genes encoding aberrant and normal epidermal growth factor receptor RNAs from A431 human carcinoma cells
###end article-title 143
###begin article-title 144
A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter
###end article-title 144
###begin article-title 145
Epidermal growth factor receptor gene promoter. Deletion analysis and identification of nuclear protein binding sites
###end article-title 145
###begin article-title 146
###xml 19 24 <span type="species:ncbi:9606">human</span>
Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins
###end article-title 146
###begin article-title 147
###xml 152 157 <span type="species:ncbi:9606">human</span>
Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells
###end article-title 147
###begin article-title 148
Isolation of genomic DNA
###end article-title 148
###begin article-title 149
Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression
###end article-title 149
###begin article-title 150
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
###end article-title 150
###begin article-title 151
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
###end article-title 151
###begin article-title 152
EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer
###end article-title 152
###begin article-title 153
###xml 73 78 <span type="species:ncbi:9606">human</span>
Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas
###end article-title 153
###begin article-title 154
Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer
###end article-title 154
###begin article-title 155
###xml 161 169 <span type="species:ncbi:9606">patients</span>
Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study
###end article-title 155
###begin article-title 156
Molecular determinants of the response of glioblastomas to EGFR kinase inhibit tors
###end article-title 156
###begin title 157
Figures and Tables
###end title 157
###begin title 158
###xml 41 48 41 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
Determination of AI for Heterozygous for CA-SSR1 and for Tumors Having a Deletion Mutation in Exon 19 or the L858R Mutation in Exon 21
###end title 158
###begin p 159
###xml 57 64 57 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
Representative wave patterns are illustrated for (A) the CA-SSR1 allele and (B) the deletion mutation in exon 19 or L858R mutation in exon 21. Both tumors and corresponding lung tissue were analyzed. Note in (A) the ratio of shorter allele to longer allele is actually 1.3:1, as illustrated for lung #423, due to artifactual preferential amplification of the short allele. Thus, an appropriate correction factor is applied.
###end p 159
###begin title 160
###xml 43 47 43 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
Relationship between SNP -216 Variants and EGFR mRNA Expression in HBEC Cultures
###end title 160
###begin p 161
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 32 36 32 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ACTB</italic>
(A) Standard curves of EGFR and ACTB. Both slopes of cycle threshold (Ct)/log copies (Log Co) were mostly coincidental.
###end p 161
###begin p 162
###xml 36 45 36 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR/ACTB</italic>
###xml 122 126 122 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 175 179 175 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
(B) Comparison of relative ratio of EGFR/ACTB among three groups of cultured cells (HBECs, lung cancer cell lines without EGFR mutations [WT], and lung cancer cell lines with EGFR mutations [MU]).
###end p 162
###begin p 163
###xml 101 108 101 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
(C) Comparison of relative ratio of HBECs having SNP -216 G/G versus G/T or T/T. mCA, mean number of CA-SSR1 repeats.
###end p 163
###begin title 164
The Correlation between AI and Allelic Ratio
###end title 164
###begin p 165
###xml 41 48 41 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 173 174 173 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 174 175 174 175 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 185 188 185 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p =</italic>
###xml 235 236 235 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 236 237 236 237 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 247 250 247 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p &lt;</italic>
###xml 272 273 272 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 273 274 273 274 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 284 287 284 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p &lt;</italic>
The correlation between allelic ratio of CA-SSR1 (shorter allele/longer allele) and the allelic ratio (AR) of mutant (MU) to WT allele of (A) the exon 19 in-frame deletion (r2 = 0.394, p = 0.011), (B) the exon 21 L858R point mutation (r2 = 0.927, p < 0.001), or (C) both (r2 = 0.594, p < 0.001) in the same mutant cases.
###end p 165
###begin title 166
###xml 62 69 62 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 81 85 81 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
Flow Chart for Examination of the Relationship between AIs of CA-SSR1 Length and EGFR Mutations
###end title 166
###begin title 167
###xml 59 63 59 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
Hypothesized Allele-Specific Mutation and Amplification of EGFR in Lung Cancers
###end title 167
###begin p 168
We hypothesized that CA-SSR1 polymorphism occurs, mutations (M) target the EGFR allele with the shorter CA-SSR1 repeat number, and then there is allele-specific amplification. These three events, targeting the same allele, would be predicted to result in greater protein production than random allelic occurrence.
###end p 168
###begin p 169
Summary of Investigations Performed, Results, and Their Implications
###end p 169
###begin p 170
Summary of Germline (Blood) and Malignant and Non-Malignant Lung Tissues Examined
###end p 170
###begin p 171
###xml 20 24 20 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 64 72 <span type="species:ncbi:9606">Patients</span>
The Distribution of EGFR Genotypes by Ethnicity for Lung Cancer Patients
###end p 171
###begin p 172
###xml 60 67 60 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
###xml 83 91 <span type="species:ncbi:9606">Patients</span>
Ethnic Differences in Distribution of the Allele Lengths of CA-SSR1 in Lung Cancer Patients
###end p 172
###begin p 173
###xml 42 49 42 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
The Relationship between Repeat Length of CA-SSR1 and SNPs
###end p 173
###begin p 174
###xml 61 68 61 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
Ethnic Differences in the Relationship between the Length of CA-SSR1 and SNPs -191 and -216
###end p 174
###begin p 175
###xml 38 45 38 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
Frequencies of AI of Either Allele of CA-SSR1 by Ethnicity
###end p 175
###begin p 176
###xml 21 28 21 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CA-SSR1</italic>
Frequencies of AI of CA-SSR1 by Ethnicity
###end p 176
###begin p 177
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests:</bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 177
###begin p 178
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
###xml 817 821 817 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 323 329 <span type="species:ncbi:8164">Suzuki</span>
###xml 836 842 <span type="species:ncbi:8164">Suzuki</span>
###xml 913 921 <span type="species:ncbi:9606">patients</span>
###xml 976 984 <span type="species:ncbi:9606">patients</span>
###xml 1154 1162 <span type="species:ncbi:9606">patients</span>
Author contributions. M. Nomura, H. Shigematsu, P. Estess, M. Siegelman, and A. F. Gazdar designed the study. M. Nomura, H. Shigematsu, T. Takahashi and I. I. Wistuba collected data or performed experiments for the study. M. Nomura made the primer sets for the target genes and modified the conditions of PCR reactions. M. Suzuki, H. Shigematsu, and I. I. Wistuba collected the samples for the study and their clinicopathological data. A. F. Gazdar supervised the analysis of the data. M. Nomura, L. Li, Z. Feng, H. Kato, J. D. Minna, and A. F. Gazdar analyzed the data. P. Estess interpreted early data, designed subsequent approaches, and provided expertise in experimental approaches. M. Siegelman provided technical expertise and instrumentation to perform the analysis. A. Marchetti analyzed the DNA samples for EGFR mutations. M. Suzuki, H. Shigematsu, A. Marchetti, M. R. Spitz, and I. I. Wistuba enrolled patients. A. Marchetti collected tissues and data from Italian patients in the study and extracted DNA samples from tissues. M. R. Spitz provided the DNA samples from normal individuals in the US. I. I. Wistuba provided the DNA samples from patients in US. J. W. Shay and J. D. Minna provided HBECs. All authors contributed to writing the paper.
###end p 178
###begin p 179
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding:</bold>
Funding: This research was supported by grants from the Specialized Program of Research Excellence in Lung Cancer (P50CA70907) and the Early Detection Research Network (5U01CA8497102), National Cancer Institute, Bethesda, Maryland. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 179

